DSM and CVC finalize partnership for Polymer Intermediates and Composite Resins

03-Aug-15

Royal DSM, the Life Sciences and Materials Sciences company, and CVC Capital Partners (CVC), one of the world's leading investment advisory firms, announced that the partnership for DSM's activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins through the formation of a new company, ChemicaInvest B.V., has been finalized. The partnership was announced on 16 March 2015. With all regulatory approvals now received, DSM and CVC have completed the transaction effective as per 31 July 2015. All approximately 1,900 employees have transferred to ChemicaInvest, which is 65% owned by CVC and 35% by DSM. DSM contributed its global caprolactam business (Europe, North America, its 60% stake in DNCC (China) and the caprolactam licensing business), acrylonitrile business and composite resins business including its 75% stake in JDR (China). DSM's 65% stake in the service organization Sitech Services held via its caprolactam and acrylonitrile businesses was also transferred. ChemicaInvest operates as an independent company with three business units: caprolactam, acrylonitrile and composite resins.